Vitaeris, Inc. logo

Vitaeris, Inc.

Vitaeris is a clinical stage biopharmaceutical company dedicated to the development of a novel investigational approach to address antibody mediated rejection. Antibody mediated rejection has been recognized as the principal cause of late graft loss in solid organ transplant recipients. Vitaeris' focus is on Clazakizumab, a potent humanized best-in-class monoclonal antibody targeting the cytokine interleukin-6 (IL-6).

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.vitaerisbio.com
Founded
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Suite 1500 - 355 Burrard St., BC V6C 2G8
Vancouver
Canada
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/vitaeris-inc.” connections=”true” suffix=””]